<DOC>
	<DOCNO>NCT01597739</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy JNJ-40346527 200 mg/day ( 100 mg twice daily ) 12 week , compare placebo , patient active rheumatoid arthritis ( RA ) despite disease-modifying antirheumatic drug ( DMARD ) therapy .</brief_summary>
	<brief_title>A Study JNJ-40346527 Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy</brief_title>
	<detailed_description>This randomize ( treatment assign chance , like flip coin ) , multicenter , double-blind ( neither physician patient know treatment patient receives ) , parallel-group ( group patient treat time ) study . JNJ-40346527 compare placebo , inactive substance use test whether drug real effect . Patients receive study medication 12 week continue permit , stable DMARD therapy ( methotrexate [ MTX ] , sulfasalazine [ SSZ ] , and/or hydroxychloroquine [ HCQ ] ) Week 12 . A follow-up visit occur 4 week dose complete . The maximum length patient participation 22 week , include 6-week screening period . Other study visit occur study , patient safety monitor .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis ( RA ) least 6 month prior screen Have positive , positive screening , either anticyclic citrullinated peptide ( antiCCP ) antibody rheumatoid factor ( RF ) serum Have active RA least 6 swollen 6 tender joint , use 66/68 joint count time screen baseline , serum Creactive protein ( CRP ) &gt; = 0.80 mg/dL screen Have treat tolerate least one follow medication minimum 6 month prior screen must stable dose minimum 8 week prior screen : methotrexate ( MTX ) treatment dosages 7.5 25 mg/week , inclusive ; sulfasalazine exceed 3 g/d ; hydroxychloroquine exceed 400 mg/d If use nonsteroidal antiinflammatory drug ( NSAIDs ) , analgesic regularly RA , patient must stable dose least 2 week prior first administration study agent . If use NSAIDs analgesic RA , patient must receive NSAIDs analgesic least 2 week prior first administration study agent If use oral corticosteroid , must stable dose &lt; = 10 mg/day prednisone equipotent dose another oral corticosteroid least 2 week prior first administration study agent . If use corticosteroid , patient must receive oral corticosteroid least 2 week prior first administration study agent Has inflammatory disease RA , include limited adult onset Still 's disease , psoriatic arthritis , ankylose spondylitis , systemic lupus erythematosus , Lyme disease might confound evaluation benefit study agent therapy Has history juvenile idiopathic arthritis ( JIA ) Has current sign symptom liver renal insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive , uncontrolled Has treat time frame specify nonbiologic diseasemodifying antirheumatic drug ( DMARDs ) , except MTX , sulfasazine , hydroxychloroquine , include , limited : Dpenicillamine , oral parenteral gold salt , azathioprine , cyclosporine , tacrolimus , mycophenolate mofetil within 4 week prior first administration study agent ; leflunomide within 12 week prior first administration study agent unless subject undergone drug elimination procedure least 4 week prior first administration study agent ; investigational nonbiologic DMARD within 4 week prior first administration study agent 5 halflives DMARD , whichever longer Has ever receive approved investigational biologic antirheumatic agent . These agent include , limited , infliximab , golimumab , certolizumab pegol , etanercept , adalimumab , abatacept , rituximab , tocilizumab , anakinra . Has receive drug potently inhibit induce cytochrome P450 ( CYP450 ) 3A4 , CYP2C8 , CYP2C19 isoforms within 2 week within 5 halflives drug , whichever longer , prior first dose study medication Has receive intraarticular , epidural , intravertebral , intramuscular , intravenous corticosteroid , include adrenocorticotropic hormone , within 4 week prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy</keyword>
	<keyword>Disease-modifying antirheumatic drug</keyword>
</DOC>